Contents Link Navigation Link
PIPELINE

Targeting, Attacking, and Eradicating Cancers®

Development Pipeline

Targeting, Attacking, and Eradicating Cancers®

PRECLINICAL
CLINICAL (PEXA-VEC, JX-594)
PHASE I
  • PEXA-VEC + REGN2810*Renal Cell Carcinoma 2L
  • PEXA-VEC + PD-L1 + CTLA4Colorectal Cancer 2L/3L
  • nih
  • PEXA-VEC + OPDIVOLiver Cancer
  • transgene
  • PEXA-VEC + YERVOYSolid Tumors
  • transgene
  • PEXA-VEC (neoadjuvant)Solid Tumors
  • transgene
  • PEXA-VEC + PD-L1**Liver Cancer
  • pharm
  • SillaJen-proprietary assets (Unpartnered with full global rights intact)
  • SillaJen is global sponsor
  • Transgene-sponsored study
  • PI-sponsored study
  • Lee’s Pharma-sponsored study

* Study start expected in 2017
** Study start expected in 2018